JPMORGAN CHASE & CO - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$1,724,872
-49.1%
62,677
-37.2%
0.00%
Q2 2023$3,386,995
+31.4%
99,823
+39.4%
0.00%
Q1 2023$2,576,907
+120203.8%
71,613
+49.0%
0.00%
Q4 2022$2,142
-99.8%
48,055
+12.0%
0.00%
Q3 2022$1,206,000
+5.6%
42,899
+1.3%
0.00%
Q2 2022$1,142,000
-4.0%
42,346
+21.4%
0.00%
Q1 2022$1,189,000
-75.9%
34,888
-72.7%
0.00%
-100.0%
Q4 2021$4,939,000
-56.7%
127,834
-39.5%
0.00%0.0%
Q3 2021$11,417,000
+2151.9%
211,453
+1292.1%
0.00%
Q2 2021$507,000
+25250.0%
15,189
+13963.9%
0.00%
Q1 2021$2,000
-33.3%
108
-35.3%
0.00%
Q4 2020$3,000
+200.0%
167
+153.0%
0.00%
Q3 2020$1,0000.0%660.0%0.00%
Q2 2020$1,000660.0%0.00%
Q1 2020$0660.0%0.00%
Q4 2019$0660.0%0.00%
Q3 2019$0660.0%0.00%
Q2 2019$0660.0%0.00%
Q1 2019$0660.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders